Pregnancy of unknown location in a cohort of patients treated with methotrexate

Ghadear Shukr
Henry Ford Health System, gshukr1@hfhs.org

Omar Zwain
Sanjana Kulkarni
David Eisenstein
Henry Ford Health System, deisens1@hfhs.org

Follow this and additional works at: https://scholarlycommons.henryford.com/merf2019clinres

Recommended Citation
Shukr, Ghadear; Zwain, Omar; Kulkarni, Sanjana; and Eisenstein, David, "Pregnancy of unknown location in a cohort of patients treated with methotrexate" (2019). Clinical Research. 2.
https://scholarlycommons.henryford.com/merf2019clinres/2

This Poster is brought to you for free and open access by the Medical Education Research Forum 2019 at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Clinical Research by an authorized administrator of Henry Ford Health System Scholarly Commons.
Introduction: To determine the prevalence of pregnancy of unknown location (PUL) in patients treated with Methotrexate (MTX) for nonsurgical diagnosis of ectopic pregnancy (EP). To determine the β-hCG treatment outcomes.

Methods: Retrospective cohort study of patients who received MTX for treatment of EP over a 10-year period in an urban-based healthcare system. Wilcoxon test was used for statistical analysis.

Results: A total of 150 pregnancies were identified as treated with MTX over a 10-year period. Pregnancies were classified based on reviews of ultrasound as pregnancy of unknown location (PUL), ectopic pregnancy (EP), or intrauterine pregnancy (IUP). 47 were classified as PUL. 101 EP. 2 IUP. Approximately 1/3 of patients treated with MTX were PULs. The average baseline β-hCG was 2960 MIU/mL and the average β-hCG at treatment was 4188 MIU/mL for the entire cohort. Resolution of β-hCG levels with one dose of MTX differed between pregnancy types with PULs prescribed MTX at a lower β-hCG level on day of treatment (56% vs 27% at β-hCG of less than 1000 MIU/mL) compared to EP. Additionally, 61% of the entire cohort were treated with 2 data points or less. 38% of PUL were treated with 1 to 2 β-hCG values and 82% PUL were treated at β-hCG <2000 MIU/mL. Of the two IUPs, β-hCG level at treatment was 6267 MIU/mL and 13353 MIU/mL.

Conclusion: There may be an underappreciated risk of inadvertent administration of Methotrexate to patients with early IUP. A minimum of three β-hCG assays over seven days in the diagnostic algorithm for EP would decrease treatment of PUL.

Background

• In spite of the seriousness of inadvertent teratogenic effects to IUP treatment, literature on methotrexate treatments focuses on success rates, and there is no literature that assesses the incidence of such events.

• To date no research has been performed to analyze how often methotrexate is used in the setting of PUL. PUL is defined as pregnancies wherein β-hCG levels continue to rise abnormally with ambiguous ultrasound findings.

• The purpose of this study is to characterize β-hCG levels and ultrasound findings present at the time of methotrexate administration in patients diagnosed with an ectopic pregnancy and produce recommendations for modifying current clinical guidelines to minimize the risk of unnecessary or inadvertent methotrexate exposure to pregnancies labeled as PUL that are subsequently identified as IUP.

Results

• A total of 150 pregnancies were identified as treated with MTX over a 10-year period.

• Pregnancies were classified based on reviews of ultrasound as: 1) pregnancy of unknown location (PUL) N=47, 2) ectopic pregnancy (EP) N=101 or 3) Intrauterine pregnancy (IUP) N=2

• Approximately 1/3 of all patients treated with MTX were PULs

• Average baseline B-hCG was 2960 MIU/mL for the entire cohort

• Average b-hCG at treatment was 4188 MIU/mL for the entire cohort.

• 61% of the entire cohort were treated with 2 data points or less

• PULs were prescribed MTX at a lower b-hCG level on treatment day

• Resolution occurred more often (56% vs 27%) at b-hCG of less than 1000 MIU/mL for PUL compared to EP

• 38% of PUL were treated with 1-2 b-hCG values.

• 82% PUL were treated at b-hCG <2000 MIU/mL.

• Of the two identified IUPs, b-hCG level at treatment was 6267 MIU/mL and 13353 MIU/mL.

CONCLUSION

One-third of the patients treated with Methotrexate for EP were classified as PUL and two IUPs were treated with Methotrexate.

There is an underappreciated risk of inadvertent administration of Methotrexate to patients with early IUP.

A minimum of three β-hCG assays in the diagnostic algorithm for EP would decrease treatment of PUL.

Bibliography


Abstract

Background

In spite of the seriousness of inadvertent teratogenic effects to IUP treatment, literature on methotrexate treatments focus on success rates, and there is no literature that assesses the incidence of such events.

To date no research has been performed to analyze how often methotrexate is used in the setting of PUL. PUL is defined as pregnancies wherein β-hCG levels continue to rise abnormally with ambiguous ultrasound findings.

The purpose of this study is to characterize β-hCG levels and ultrasound findings present at the time of methotrexate administration in patients diagnosed with an ectopic pregnancy and produce recommendations for modifying current clinical guidelines to minimize the risk of unnecessary or inadvertent methotrexate exposure to pregnancies labeled as PUL that are subsequently identified as IUP.

Methods

Project design: Retrospective chart review

Location: A single community based healthcare institution, Henry Ford Health System

Inclusion criteria: All patients who were diagnosed with ectopic pregnancies and treated with methotrexate from 01/01/2007 - 12/31/2017.

Exclusion criteria: Patients who had an ectopic pregnancy and not treated with methotrexate or those who underwent initial conservative or surgical management.

Duration: 10 years, from 01/01/2007 - 12/31/2017.

Statistical Analysis: Wilcoxon test. All Wilcoxon test used the Fligner-Policello Test for unequal variables.